Yoshioka T, Fujita T, Kanai T, Aizawa Y, Kurumada T, Hasegawa K, Horikoshi H
Medicinal Chemistry Research Laboratories, Sankyo Co., Ltd., Tokyo, Japan.
J Med Chem. 1989 Feb;32(2):421-8. doi: 10.1021/jm00122a022.
A series of hindered phenols were investigated as hypolipidemic and/or hypoglycemic agents with ability to inhibit lipid peroxidation. 1,3-Benzoxathioles (9 and 22), phenoxypentanoic acid (34), phenoxypentanol (35a), phenoxynonanol (35b), phenylchloropropionic acid having a chromanyl group (25), and a thiazolidine compound (27) derived from 25, all having a hindered phenol group, were prepared and examined. Compound 27 showed the expected biological properties in vivo and in vitro without any liver weight increase. Biological activities of the analogous thiazolidine compounds, 43-58, were compared. Thus, (+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]- benzyl]-2,4-thiazolidinedione (27) (CS-045) was found to have all of our expected properties and was selected as a candidate for further development as a hypoglycemic and hypolipidemic agent.
研究了一系列受阻酚作为具有抑制脂质过氧化能力的降血脂和/或降血糖药物。制备并检测了1,3-苯并噻唑(9和22)、苯氧基戊酸(34)、苯氧基戊醇(35a)、苯氧基壬醇(35b)、具有色满基的苯基氯丙酸(25)以及由25衍生的噻唑烷化合物(27),它们均含有受阻酚基团。化合物27在体内和体外均表现出预期的生物学特性,且不会导致肝脏重量增加。比较了类似噻唑烷化合物43 - 58的生物活性。因此,发现(±)-5-[4-[(6-羟基-2,5,7,8-四甲基色满-2-基)甲氧基]-苄基]-2,4-噻唑烷二酮(27)(CS-045)具有我们预期的所有特性,并被选为作为降血糖和降血脂药物进一步开发的候选物。